鹰瞳科技-B2023年年度报告

CONTENTS Corporate Information2Financial Summary6Chairman’s Statement7Management Discussion and Analysis10Profiles of Directors, Supervisors andSenior Management43Corporate Governance Report53Environmental, Social and Governance Report83Report of the Directors171Report of the Supervisors213Independent Auditor’s Report216Consolidated Statement of Profit or Loss227Consolidated Statement of Comprehensive Income228Consolidated Statement of Financial Position229Consolidated Statement of Changes in Equity231Consolidated Statement of Cash Flows233Notes to The Consolidated Financial Statements237Definitions and Glossary of Technical Terms388 CORPORATE INFORMATION BOARD OF DIRECTORS Executive Directors (Chairman and chief executive officer)Ms. WANG Lin(effective from March 30, 2023)Dr. HE Chao(effective from December 29, 2023)Mr. QIN Yong(effective from December 29, 2023)Mr. GAO Fei(ceased on January 13, 2023)Dr. CHEN Yuzhong(ceased on December 29, 2023)Mr. CHEN Hailong(ceased on December 29, 2023) Non-executive Directors 20231 13202312 2920233 3020237 27 Ms. WANG Mi(ceased on January 13, 2023)Mr. CHEN Xin(ceased on December 29, 2023)Ms. ZHU Tingyao(effective from March 30, 2023 andceased on July 27, 2023) Independent Non-executive Directors Mr. NG Kong Ping AlbertDr. WU YangfengDr. HUANG Yanlin SUPERVISORS Mr. WEI YuboMs. BAI HuihuiDr. LUO Ting AUDIT COMMITTEE Mr. NG Kong Ping Albert(Chairman)Dr. HUANG YanlinDr. WU Yangfeng 32023北京鷹瞳科技發展股份有限公司CORPORATE INFORMATION REMUNERATION AND APPRAISALCOMMITTEE 20233 3020231 13 Dr. HUANG Yanlin(Chairman)Mr. NG Kong Ping AlbertMs. WANG Lin(effective from March 30, 2023)Mr. GAO Fei(ceased on January 13, 2023) NOMINATION COMMITTEE Mr. ZHANG Dalei(Chairman)Dr. HUANG YanlinDr. WU Yangfeng STRATEGY COMMITTEE Mr. ZHANG Dalei(Chairman)Mr. NG Kong Ping AlbertDr. WU Yangfeng ESG COMMITTEE Mr. ZHANG Dalei(Chairman)Ms. WANG LinDr. HE Chao AUTHORIZED REPRESENTATIVES Mr. ZHANG DaleiMs. SO Lai Shan JOINT COMPANY SECRETARIES Ms. YANG WentingMs. SO Lai Shan(ACG (CS, CGP) HKACG (CS, CGP)) HEAD OFFICE, REGISTERED OFFICE ANDPRINCIPAL PLACE OF BUSINESS IN THEPRC 22421 Room 21, 4th Floor, Building 2, A2 YardWest Third Ring North RoadHaidian DistrictBeijingPRC PRINCIPAL PLACE OF BUSINESS INHONG KONG 33191901 Room 1901, 19/F, Lee Garden One33 Hysan AvenueCauseway BayHong Kong H H SHARE REGISTRAR 1617 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong HONG KONG LEGAL ADVISER 1526 Kirkland & Ellis26/F, Gloucester TowerThe Landmark15 Queen’s Road CentralHong Kong PRC LEGAL ADVISER 2022–31 Zhong Lun Law Firm22–31/F, South Tower of CP Center20 Jin He East AvenueChaoyang DistrictBeijingPRC AUDITOR 97927 Ernst & Young Certified Public AccountantsRegistered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry BayHong Kong STOCK CODE 2251 2251 www.airdoc.com COMPANY WEBSITE www.airdoc.com FINANCIAL SUMMARY A summary of the results and of the assets and liabilities ofthe Group for the last five financial years, as extracted fromthe audited financial information and financial statements isset out below: CHAIRMAN’S STATEMENT 2023 In this era filled with challenges and opportunities, I amhonored to share with you the remarkable achievementsAirdoc has made in 2023. Over the past year, by adhering toour commitment to putting clients first, coupled with ourprofound understanding of technology and keen insightsinto market demands, we have driven business growththrough resilience and innovation. 2023 As pioneers in the industry, we are dedicated to leveragingAI technology to provide comprehensive solutions for theearly detection, diagnosis, and health risk assessment ofchronic fundus diseases and ophthalmic disorders. In 2023,our independently developed AI retinal imaging deep learningplatform continued to maintain a leading position in theindustry. Our innovative products and services have not onlybeen widely recognized in the Chinese market but have alsosuccessfully entered international markets in Southeast Asiaand the Middle East. Airdoc-AIFUNDUS (1.0)(CE MDR)AI-FUNDUSCAMERA-P In terms of product development, we have made significantprogress. Airdoc-AIFUNDUS (1.0) received certificationunder the European Union Medical Device Regulation (CEMDR), signifying that our technology and products havereached an international leading level. Additionally, ourAI-FUNDUSCAMERA-P and myopia treatment productshave received special commendation gold awards internationally,which not only is a recognition of our technologicalinnovation capabilities but also lays a solid foundation forour expansion into the global market. CHAIRMAN’S STATEMENT 20232023683AI31,459AIAI On the business front, the Company achieved a significantgrowth in revenue in 2023, with both customer numbers andunit prices increasing, and a significant narrowing of losses.This success is attributable to our brand, which is highlyregarded by serio